Change over period: —
NSE · ZYDUSLIFE
ZYDUSLIFE
-3.5% from the 52-week high · +39.7% above the low
Zydus Lifesciences Ltd. engages in the discovery, development, and manufacture of pharmaceutical products under Zydus brand. The company is headquartered in Ahmedabad, Gujarat and currently employs 23,026 full-time employees. The firm is engaged in the research and development, manufacturing, marketing and selling of finished dosage human formulations, such as generics and specialty formulations, including biosimilars and vaccines; active pharmaceutical ingredients (APIs); animal healthcare products, and consumer wellness products. Its products include Bilypsa (saroglitizar), Oxemia (desidustat), Ujvira (biosimilar Kadcyla), and Exemptia. The company offers Bilypsa drug for non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH). Desidustat is an oral, small molecule hypoxia-inducible factor-prolyl hydroxylase (HIF-PH) inhibitor, which is used for the treatment of anemia in chronic kidney disease (CKD) patients. The company is also developing an oral small molecule ZYIL1, targeted at selectively suppressing inflammation caused by the NLRP3 inflammasome. Its ZyCoV-D is a plasmid deoxyribonucleic acid (DNA) vaccine for COVID-19.
The short version. ZYDUSLIFE reported revenue of ₹7,910 crore for Sep 2026, up 29.2% from a year earlier. Net profit was ₹926 crore (down 26.4% year on year). Return on equity was 18.6% in Mar 2026. Promoter holding was 75.01% in Sep 2026, up 0.03 points over 8 quarters.
1 · The price
How has the stock traded?
ZYDUSLIFE trades 3.5% below its 52-week high and 39.7% above its 52-week low.
2 · The business
Is it growing?
Sep 2026 revenue of ₹7,910 cr.
Sep 2026 net profit of ₹926 cr.
8.9 pts lower than a year earlier.
Revenue compounded at 16.7% over the same 3 years.
Reported results · ₹ crore
Revenue and profit
Show the numbers
Quarterly
| Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | 7910 | 8017 | 7587 | 6864 | 6123 | 6574 | 6528 | 5269 |
| Net profit | 926 | 940 | 1272 | 1042 | 1259 | 1467 | 73 | 1024 |
| Net margin % | 11.7 | 11.7 | 16.8 | 15.2 | 20.6 | 22.3 | 1.1 | 19.4 |
| EPS (₹) | 9.28 | 9.42 | 12.65 | 10.36 | 12.51 | 14.58 | 0.72 | 10.17 |
Annual
| FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | 27148 | 23242 | 19547 | 17237 | 15265 | 15102 | 14253 | 13166 |
| Net profit | 5040 | 4526 | 3860 | 1960 | 4487 | 2134 | 1177 | 1849 |
| Net margin % | 18.6 | 19.5 | 19.7 | 11.4 | 29.4 | 14.1 | 8.3 | 14.0 |
| EPS (₹) | 50.09 | 44.97 | 38.36 | 19.37 | 43.83 | 20.84 | 11.49 | 18.06 |
3 · The quality
How well does it turn capital into profit?
Return on equity was 18.6% in Mar 2026; debt to equity is 0.43.
Profitability · 4 years
Returns and margins
| Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | |
|---|---|---|---|---|
| Return on equity % | 18.6 | 18.9 | 19.5 | 11.2 |
| Return on capital % | 19.2 | 22.0 | 20.4 | 13.4 |
| EBITDA margin % | 30.6 | 30.2 | 28.5 | 19.8 |
| Net margin % | 18.2 | 19.2 | 19.5 | 11.2 |
Compound growth
Revenue vs profit
| 3 years | 5 years | |
|---|---|---|
| Revenue CAGR | 16.7% | 12.8% |
| Profit CAGR | 37.0% | 18.8% |
4 · The owners
Who holds it, and are they adding?
Up 0.03 pts over 8 quarters.
Down 0.48 pts over 8 quarters.
Up 0.63 pts over 8 quarters.
+66 versus the previous month.
Shareholding pattern (%)
Quarter by quarter
| Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 | Change | |
|---|---|---|---|---|---|---|---|---|---|
| Promoter | 74.98 | 74.99 | 74.99 | 74.99 | 75.0 | 75.0 | 75.01 | 75.01 | +0.03 |
| FII | 7.53 | 7.32 | 7.13 | 7.34 | 7.06 | 6.95 | 6.88 | 7.05 | -0.48 |
| DII | 10.65 | 11.01 | 11.13 | 10.86 | 11.09 | 11.2 | 11.27 | 11.28 | +0.63 |
| Public | 6.84 | 6.68 | 6.74 | 6.8 | 6.85 | 6.86 | 6.83 | 6.66 | -0.18 |
Mutual fund holdings · Oct 2026
230 schemes hold this stock
164 the month before.
- quant Aggressive Hybrid Fund10.37% of NAV
- quant Healthcare Fund10.25% of NAV
- quant Consumption Fund8.02% of NAV
- quant Large & Mid Cap Fund6.94% of NAV
- quant Mid Cap Fund6.11% of NAV
- SAMCO LARGE CAP FUND5.86% of NAV
- quant Quantamental Fund5.02% of NAV
- quant Multi Cap Fund4.09% of NAV
5 · The model view
What does our factor model say?
Factor scores, model flags and screen results for ZYDUSLIFE are part of the Wright portfolio review.
Run your free portfolio reviewWatchouts
What to review
Model flags are shown inside the portfolio review, alongside your other holdings.
Related stocks
Other Pharmaceuticals & Biotechnology stocks
Quick answers
Common questions about ZYDUSLIFE
What is the ZYDUSLIFE share price?
ZYDUSLIFE (ZYDUSLIFE) last closed at ₹1,200.00, down 0.17% on the day. Its 52-week range is ₹860.60 to ₹1,245.50.
What is the market cap of ZYDUSLIFE?
ZYDUSLIFE has a market capitalisation of about ₹102,404 crore.
How are ZYDUSLIFE's latest results?
ZYDUSLIFE reported revenue of ₹7,910 crore for Sep 2026, up 29.2% from a year earlier. Net profit was ₹926 crore (down 26.4% year on year). Return on equity was 18.6% in Mar 2026. Promoter holding was 75.01% in Sep 2026, up 0.03 points over 8 quarters.
Who owns ZYDUSLIFE?
As of Sep 2026, shareholding was: Promoter 75.01%, FII 7.05%, DII 11.28%, Public 6.66%.
How many mutual funds hold ZYDUSLIFE?
230 mutual fund schemes held ZYDUSLIFE in October 2026. That compares with 164 the month before.
Corporate actions
Recent dividends, bonuses and splits
- 25 Jul 2025 · Final Dividend - Rs. 11
- 26 Jul 2024 · Final Dividend - Rs. 3
- 28 Jul 2023 · Final Dividend - Rs. 6
- 28 Jul 2022 · Final Dividend - Rs. 2.5
- 28 Jul 2021 · Final Dividend - Rs. 3.5
- 23 Mar 2020 · Interim Dividend - Rs. 3.5
Financials are as reported by the company (consolidated), in ₹ crore. Source: FinEdge exchange filings feed. Figures can differ from other sites because of one-off items and restatements. Callouts above are arithmetic on reported data, not recommendations.
Research data on this page is provided under Wright Research's SEBI Research Analyst registration. The Terms & Conditions of our Research Analyst services apply.